Grupo Oncoclinicas

What Grupo Oncoclinicas does

Grupo Oncoclinicas (Oncoclínicas&Co, B3: ONCO3) is a publicly traded Brazilian oncology care platform founded in 2010 by oncologist Bruno Ferrari in Belo Horizonte. The company operates the largest cancer treatment network in Latin America with 140+ clinics, laboratories, and integrated cancer centers across 40 Brazilian cities, employing over 2,700 medical professionals. Service lines span the full oncology continuum — chemotherapy, radiotherapy, immunotherapy, targeted therapy, bone marrow transplant, oncological surgery, and palliative care — delivered alongside a dedicated precision medicine arm, OC Medicina de Precisão, which integrates pathological anatomy, genomics, and Big Data laboratories to support diagnosis and treatment selection via molecular journeys. Adjacent revenue streams include DeLife (oral oncology medications), OC Vacinas (vaccination program launched April 2024), clinical research across seven units since 2018, the OC Telemedicina platform, and the OC Franquias franchise channel.

The business model is B2B2C: services are billed primarily through contracted health insurance (convênio) providers — over 70 plans including UNIMED, Bradesco, SulAmérica, Porto Seguro, and Amil — with supplementary private-pay and telemedicine revenue. Go-to-market is sales-led via direct clinic access, enterprise contracts with insurers, and a multi-channel patient acquisition stack including a proprietary mobile app, telemedicine platform, social media presence, and an educational content engine. Distribution is complemented by an exclusive clinical research partnership with Dana-Farber Cancer Institute (Harvard Medical School affiliate) and certified laboratory operations under ONA Level 3, PALC, PICQ, and PACQ accreditations.

As of early 2026, the company is in severe financial distress: founder-CEO Bruno Ferrari stepped down in February 2026 amid governance concerns tied to Banco Master and a near-50% stock decline, CFO Camille Faria departed shortly after, and net debt stands at approximately R$4 billion with EBITDA turning deeply negative in 2025. A proposed R$1 billion+ investment from insurer Porto Saúde and diagnostics group Fleury — alongside plans to file for judicial (creditor) recovery in April 2026 — frames the company as a turnaround/restructuring candidate despite its leading operational footprint.

Name

Grupo Oncoclinicas

Legal name

ONCOCLINICAS DO BRASIL SERV MEDICOS SA

Website

https://grupooncoclinicas.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Grupo Oncoclinicas is the largest cancer treatment network in Latin America, operating 140+ oncology clinics and precision medicine laboratories across 40 Brazilian cities and serving insured patients through 70+ contracted health plans, currently in financial restructuring.

Ownership category

akta.pro rank

Product category

Oncology Healthcare Services

NAICS

Ambulatory Health Care Services (621), Offices of Physicians (62111), Medical and Diagnostic Laboratories (6215), Other Ambulatory Health Care Services (6219)

SIC

Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

Keywords

• Oncology treatment services
• Cancer care network
• Precision medicine diagnostics
• Radiotherapy chemotherapy
• Hematology bone marrow transplant

Headquarters

HQ city

Belo Horizonte

HQ country

Brazil

HQ region

Latin America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Others

Revenue model

1. Healthcare Services Revenue: Oncoclinicas generates revenue primarily through providing oncology services including consultations, chemotherapy, radiotherapy, surgery, diagnostics, and specialized cancer treatments through its network of 140+ clinics. Services are billed primarily through health insurance (convênio) providers and some private pay patients.
2. Diagnostic Testing: Revenue from pathology, genomic testing, and molecular diagnostics services performed at the OC Medicina de Precisão laboratories, serving both internal patients and external referring physicians.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Grupo Oncoclinicas operates one of Latin America's largest oncology service networks, delivering comprehensive cancer care through 140+ clinics, laboratories, and integrated treatment centers across 40 Brazilian cities. The company provides end-to-end oncology services including precision medicine (pathological anatomy, genomics, and big data diagnostics), chemotherapy, radiotherapy, oncological surgery, immunotherapy, targeted therapy, bone marrow transplant, palliative care, and clinical research programs, supported by a proprietary telemedicine platform and contracted with 70+ health insurance providers.

Product overview

Oncoclinicas&Co is a comprehensive oncology services platform operating as a network of over 140 units (clinics, hospitals, and laboratories) across 40 cities in Brazil. The offering is organized around integrated care delivery combining a core platform of diagnostic and treatment services with specialized precision medicine capabilities. The main product pillars include: OC Medicina de Precisão (central precision medicine hub with pathological anatomy, genomics, and big data labs), OC Linha de Cuidado (care coordination service), comprehensive treatment services (chemotherapy, radiotherapy, immunotherapy, targeted therapy, bone marrow transplant, and oncological surgery), clinical research program, telemedicine platform (OC Telemedicina), and supportive services including DeLife (oral medications), OC Vacinas (vaccination), palliative care, and professional education (OC Academia, OC Journal). The network operates under a hub-and-spoke model with flagship Cancer Centers and franchise locations (OC Franquias).

Differentiator

Problem solved

Functional benefit

Brands

• OC Medicina de Precisão: Precision Medicine Center encompassing Pathological Anatomy, Genomics and Big Data laboratories for diagnosis and prognosis
• OC Linha de Cuidado
• OC Vacinas
• DeLife
• OC Telemedicina
• OC Cuidados Paliativos
• Programa de Pesquisa Clínica

Products and services

• OC Medicina de Precisão (Precision Medicine Center) Comprehensive precision medicine center encompassing Pathological Anatomy, Genomics, and Big Data laboratories offering a complete molecular portfolio (immunohistochemistry, NGS panels, liquid biopsy, germline testing, digital pathology) for diagnostic, predictive, and prognostic purposes in oncology.
• OC Linha de Cuidado (Care Line) Continuous care coordination service that accompanies cancer patients throughout their treatment journey from diagnosis to clinical outcome, providing agility in exams, radiotherapy, surgeries, consultations, and diagnostic procedures.
• OC Vacinas (Vaccination Program) Vaccination service for patients and family members at affiliated Oncoclinicas units, focused on disease prevention and increased vaccination coverage in line with national guidelines.
• Clinical Research Program Clinical research program with centralized management across seven units in Brazil, contributing to scientific development and providing access to innovative oncology treatments for patients.
• OC Telemedicina (Telemedicine)

Quantifiable outcome

• Largest oncology group in Latin America with 140+ units
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• Dana-Farber Cancer InstitutecoreStrategic or Co-development PartnerExclusive partnership in Brazil with Dana-Farber Cancer Institute, affiliated with Harvard Medical School - one of the world's leading cancer treatment and research centers. This partnership supports clinical research, knowledge exchange, and access to cutting-edge oncology practices.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Oncologia D'Or: Direct competitor within the top 3 oncology groups in Brazil, backed by Rede D'Or São Luiz. Operates cancer treatment centers competing with Oncoclinicas for the same patient population, health insurance contracts, and specialist physicians across Brazilian cities.
• Rede Américas: Third member of Brazil's top 3 oncology groups (alongside Oncoclinicas and Oncologia D'Or). Operates oncology clinics and treatment centers with similar patient mix, payer relationships, and competitive positioning in the same Brazilian private oncology market.
• A.C. Camargo Cancer Center: One of Brazil's leading cancer specialty hospitals, providing comprehensive oncology diagnosis, treatment, and research. Comparable to Oncoclinicas in oncology specialization, with similar clinical research programs and multidisciplinary care model, though operating as a single flagship institution rather than a distributed network.

Broad incumbents

• Rede D'Or São Luiz: Brazil's largest hospital chain and parent of Oncologia D'Or. While a broad incumbent across many specialties, Rede D'Or's dedicated oncology arm makes it a major competitor for cancer patients and specialists in the same Brazilian market.
• Fleury Group: Major Brazilian diagnostic and laboratory medicine company currently negotiating a co-investment with Porto Saúde in Oncoclinicas. Competes with Oncoclinicas' OC Medicina de Precisão division in pathology, genomics, and diagnostic testing while also serving as a referral partner.
• Dasa (Diagnósticos da América): Latin America's largest medical diagnostic company, competing directly with Oncoclinicas' OC Medicina de Precisão in clinical laboratory, imaging, and molecular/genomic testing services. Operates across Brazil with similar B2B and B2C diagnostic offerings.
• Hospital Israelita Albert Einstein: Premium Brazilian hospital system offering comprehensive oncology services including diagnosis, treatment, and research. Competes with Oncoclinicas for high-end private patients and specialist physicians, though positioned more broadly across multiple specialties.
• Hospital Sírio-Libanês: High-end São Paulo-based hospital offering strong oncology programs alongside other specialties. Competes for the same private insured patient segment and employs many of the same specialist physicians as Oncoclinicas in the premium oncology market.

Others

• UnitedHealth Group (Amil): Major US-based health insurer operating Amil in Brazil, one of the largest payers in Oncoclinicas' network. Not a direct clinical competitor but a critical payer and increasingly vertically integrated into care delivery, potentially conflicting with Oncoclinicas' independent provider model.

Regional players

• MD Anderson Cancer Center: World-leading US-based cancer specialty hospital and research center, serving as the global benchmark for comprehensive oncology care. Comparable in care model (multidisciplinary, research-driven, precision medicine-enabled) though operating in a different geography and serving as an aspirational peer rather than a direct competitor.

Market position

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/oncoclinicas
• YouTubeyoutube.com/channel/UCTLjB1xqQs88RiW1JsQHDpQ
• Facebookfacebook.com/GrupoOncoclinicas
• LinkedInlinkedin.com/company/grupooncoclinicas
• Instagraminstagram.com/grupooncoclinicas
• TikToktiktok.com/@oncoclinicas

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grupo Oncoclinicas